Sanofi makes $3.2B bet on mRNA by acquiring partner Translate Bio

In the rush to snatch up medicines based on messenger RNA, or mRNA, Sanofi (NYSE: SNY) is buying its longtime partner Translate Bio (Nasdaq: TBIO) in an all-cash transaction that values the firm at $3.2 billion. The news was first reported Monday evening by Reuters. Both companies confirmed shortly after. Translate Bio, based in Lexington, has partnered with Sanofi's vaccine-making arm, Sanofi Pasteur, for about three years to make vaccines based on mRNA for a variety of illnesses including seasonal…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news